Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancer

Lin Shen*

Human epidermal growth factor receptor 2 (HER2) overexpression/amplification affects about 6.1%–23.0% of gastric cancer patients [1, 2]. All major guidelines recommend HER2 testing to guide the selection for trastuzumab treatment in metastatic gastric cancer (mGC) [3], because doublet chemotherapy with trastuzumab significantly improved overall survival (OS) in the crucial trastuzumab for gastric cancer trial (the ToGA trial) [4]. However, the unsatisfactory gain of median progression-free survival (PFS) stresses important issues of intrinsic and acquired resistance to HER2-targeted therapies [4]. Currently, the underlying molecular mechanism of trastuzumab resistance in mGC is still unclear, and the strategies to real time monitor resistance-specific aberrations are urgently needed. As circulating tumor DNA (ctDNA) carries the same genomic alterations that are present in the primary tumor [5, 6], liquid biopsy-based ctDNA profiling offers a unique opportunity for serially monitoring treatment response in a non-invasive manner, and has opened the door for identification the mechanisms of drug resistance. In a study recently published in Gut, titled “Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer”, Wang et al. [7] demonstrated for the first time that longitudinal ctDNA sequencing could promisingly predict tumor shrinkage and progression in HER2+ mGC patients under trastuzumab treatment. Based on the detected molecular alterations from the ctDNA profiling, they further dissected various mechanisms of trastuzumab resistance (Fig. 1).

In this study, the authors sequenced 416 clinically relevant genes to determine the genomic profiles of GC patients. The molecular alterations, including copy number alterations, mutations and structural variations, detected in 78 paired plasma and tissue samples (46 from HER2+ patients and 32 from HER2− patients) were used to evaluate the consistency of detection between the “liquid” and “solid” biopsies. As expected, the alterations detected in plasma provided a good representation of the status in the tumor tissues. In particular, HER2 amplification status, the major marker of HER2+ GC, detected by plasma-based ctDNA sequencing was highly consistent with that by tissue-based sequencing and fluorescence in situ hybridisation. These findings indicated that plasma-based ctDNA profiling might provide insights into HER2 amplification in HER2+ GC.

Further longitudinal analysis were perform in 97 time-course plasma samples collected from 24 HER2+ mGC patients to track the resistance during trastuzumab treatment. As compared to plasma carcinoembryonic antigen, the copy number variations (CNVs) of HER2 in ctDNA were better at tracking trastuzumab treatment response. Generally, the HER2 copy number decreased during treatment compared with baseline and levels of progressive disease (PD), indicating tumor shrinkage. Additionally, most patients with intrinsic resistance-related progression presented higher HER2 copy numbers at PD than baseline, while the patients with acquired resistance often had lower HER2 copy numbers at PD.

From the same ctDNA profiles, the authors found evidence for reported mechanisms of trastuzumab resistance in 76.5% patients. They found that the patients with multiple resistance mechanisms (PIK3CA/R1/C3 and ERBB2/4 mutations) displayed much shorter PFS during
trastuzumab treatment. These findings suggested that liquid biopsy-based ctDNA profiling can effectively capture the heterogeneity information about acquired resistance. Furthermore, they also observe several novel resistance mechanisms. One of them is the ERBB4 S774G mutation. This novel mutation can increase the sensitivity to trastuzumab treatment, suggesting for the first time that the mutation of ERBB4 play a critical role in mediating resistance to ERBB2 inhibitors in HER2+ GC. Another novel resistance mechanism is the emergence of NF1 mutations. Using in vitro and in vivo experiments, the authors demonstrated that NF1 was a resistance-related gene and could be used as a potential resistance marker of trastuzumab. NF1 lost (mutation or deletion) contributes to driving resistance of HER2-targeted therapy via elevating pMEK/ERK activation, whereas the combination of HER2 and MEK/ERK inhibitors might overcome trastuzumab resistance.

This study has some obvious limitations. First, other rare genomic or even nongenomic mechanisms of trastuzumab resistance may have been missed by the 416-gene panel. Second, the relatively small number of patient enrolled does not allow drawing definitive conclusion on the predictive value of this liquid biopsy approach. Nevertheless, the study provides helpful information to monitor the treatment response of trastuzumab and develop therapeutic strategies for the HER2+ mGC patients with trastuzumab resistance.

Abbreviations
HER2: human epidermal growth factor receptor 2; mGC: metastatic gastric cancer; OS: overall survival; ToGA: trastuzumab for gastric cancer; PFS: progression-free survival; ctDNA: circulating tumor DNA; CNV: copy number variation; PD: progressive disease; PIK3CA/R1/C3: phosphoinositide 3-kinase catalytic subunit alpha/regulatory subunit 1/catalytic subunit type 3; ERBB2/4: receptor tyrosine-protein kinase erbB-2/4; MEK/ERK: mitogen-activated protein kinase kinase/extracellular signal-regulated kinases.

Authors’ contributions
The author read and approved the final manuscript.
Acknowledgements
Not applicable.

Competing interests
The author declares no competing interests.

Availability of data and materials
Not applicable.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Not applicable.

Funding
Not applicable.

Received: 6 December 2018   Accepted: 7 December 2018
Published online: 18 December 2018

References
1. Van Cutsem E, Bang YJ, Feng-YI F, et al. Her2 screening data from toga: targeting her2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–84.

2. Chen T, Xu XY, Zhou PH. Emerging molecular classifications and therapeutic implications for gastric cancer. Chin J Cancer. 2016;35:49.
3. Bartley AN, Washington MK, Colasacco C, et al. Her2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American pathologists, American society for clinical pathology, and the American society of clinical oncology. J Clin Oncol. 2017;35(4):446–64.
4. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
5. Esposito A, Criscitiello C, Locatelli M, et al. Liquid biopsies for solid tumors: understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacol Ther. 2016;157:120–4.
6. Qin Z, Ljubimov VA, Zhou C, et al. Cell-free circulating tumor DNA in cancer. Chin J Cancer. 2016;35:36.
7. Wang DS, Liu ZJ, Lu YX, et al. Liquid biopsies to track trastuzumab resistance in metastatic her2-positive gastric cancer. Gut. 2018. https://doi.org/10.1136/gutjnl-2018-316522.